Expression of breast cancer resistance protein in peripheral T cell subsets from HIV‑1‑infected patients with antiretroviral therapy

Zhang,Jiu‑Cong; Deng,Zhi‑Yun; Wang,Yong; Xie,Fang; Sun,Li; Zhang,Fang‑Xin

doi:10.3892/mmr.2014.2282

Expression of breast cancer resistance protein in peripheral T cell subsets from HIV‑1‑infected patients with antiretroviral therapy

Authors:
- Jiu‑Cong Zhang
- Zhi‑Yun Deng
- Yong Wang
- Fang Xie
- Li Sun
- Fang‑Xin Zhang
View Affiliations

Affiliations: Department of Gastroenterology, Lanzhou General Hospital of Lanzhou Military Command, Lanzhou, Gansu 730050, P.R. China, Department of Clinical Laboratory, Lanzhou General Hospital of Lanzhou Military Command, Lanzhou, Gansu 730050, P.R. China, Department of Stress Medicine, Institute of Basic Medical Sciences, Beijing 100039, P.R. China, Department of Infectious Diseases, Tangdu Hospital, Fourth Military Medical University, Xi'an, Shaanxi 710038, P.R. China
Published online on: May 29, 2014 https://doi.org/10.3892/mmr.2014.2282
Pages: 939-946

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of the present study was to investigate the expression of breast cancer resistance protein (BCRP) in peripheral T cell subsets of human immunodeficiency virus 1 (HIV‑1)‑infected patients, and to analyze the association between the levels of BCRP expression and disease progression in HIV‑1 infection. Peripheral blood mononuclear cells (PBMCs) were obtained from HIV‑1‑infected patients (n=118), including 92 patients with antiretroviral therapy (ART) and 26 patients without a history of ART. Control samples from 30 healthy donors were also analyzed. The expression levels of BCRP in T cells were evaluated by flow cytometry. A high inter‑individual variability was observed in CD4+ and CD8+ T cells in the HIV‑1‑infected patients and healthy donors; however, the analyzed expression levels of BCRP were significantly higher in the HIV‑1‑infected group with ART than those in the group with no history of ART (P<0.01). Furthermore, the frequency of BCRP‑expressing T cells was inversely correlated with CD4+ and CD8+ T cell counts in HIV‑1‑infected patients with ART. The results suggested that BCRP expression varied among HIV‑1‑infected patients and healthy donors but was significantly higher in HIV‑1 patients undergoing ART. In conclusion, the present study suggested that overexpression of BCRP may be involved in disease progression of the HIV‑1 infection and may participate in drug resistance to ART, thus contributing to the failure of highly active ART in HIV‑1 therapeutics.

View Figures

View References

1	Meyer zu Schwabedissen HE and Kroemer HK: In vitro and in vivo evidence for the importance of breast cancer resistance protein transporters (BCRP/MXR/ABCP/ABCG2). Handb Exp Pharmacol. 201:325–371. 2011.PubMed/NCBI
2	Jones K, Bray PG, Khoo SH, Davey RA, Meaden ER, Ward SA and Back DJ: P-glycoprotein and transporter MRP1 reduce HIV protease inhibitor uptake in CD4 cells: potential for accelerated viral drug resistance? AIDS. 15:1353–1358. 2001. View Article : Google Scholar : PubMed/NCBI
3	Ni Z, Bikadi Z, Rosenberg MF and Mao Q: Structure and function of the human breast cancer resistance protein (BCRP/ABCG2). Curr Drug Metab. 11:603–617. 2010. View Article : Google Scholar : PubMed/NCBI
4	Nicolazzo JA and Katneni K: Drug transport across the blood-brain barrier and the impact of breast cancer resistance protein (ABCG2). Curr Top Med Chem. 9:130–147. 2009. View Article : Google Scholar : PubMed/NCBI
5	Zhou S, Morris JJ, Barnes Y, Lan L, Schuetz JD and Sorrentino BP: Bcrp1 gene expression is required for normal numbers of side population stem cells in mice, and confers relative protection to mitoxantrone in hematopoietic cells in vivo. Proc Natl Acad Sci USA. 99:12339–12344. 2002. View Article : Google Scholar : PubMed/NCBI
6	Kim RB, Leake BF, Choo EF, Dresser GK, Kubba SV, Schwarz UI, Taylor A, Xie HG, McKinsey J, Zhou S, et al: Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther. 70:189–199. 2001. View Article : Google Scholar : PubMed/NCBI
7	Cisternino S, Mercier C, Bourasset F, Roux F and Scherrmann JM: Expression, up-regulation, and transport activity of the multidrug-resistance protein Abcg2 at the mouse blood-brain barrier. Cancer Res. 64:3296–3301. 2004. View Article : Google Scholar : PubMed/NCBI
8	Cooray HC, Blackmore CG, Maskell L and Barrand MA: Localisation of breast cancer resistance protein in microvessel endothelium of human brain. Neuroreport. 13:2059–2063. 2002. View Article : Google Scholar : PubMed/NCBI
9	Maliepaard M, Scheffer GL, Faneyte IF, van Gastelen MA, Pijnenborg AC, Schinkel AH, van De Vijver MJ, Scheper RJ and Schellens JH: Subcellular localization and distribution of the breast cancer resistance protein transporter in normal human tissues. Cancer Res. 61:3458–3464. 2001.PubMed/NCBI
10	Gupta A, Zhang Y, Unadkat JD and Mao Q: HIV protease inhibitors are inhibitors but not substrates of the human breast cancer resistance protein (BCRP/ABCG2). J Pharmacol Exp Ther. 310:334–341. 2004. View Article : Google Scholar
11	Wang X, Furukawa T, Nitanda T, Okamoto M, Sugimoto Y, Akiyama S and Baba M: Breast cancer resistance protein (BCRP/ABCG2) induces cellular resistance to HIV-1 nucleoside reverse transcriptase inhibitors. Mol Pharmacol. 63:65–72. 2003. View Article : Google Scholar : PubMed/NCBI
12	Wang X, Nitanda T, Shi M, Okamoto M, Furukawa T, Sugimoto Y, Akiyama S and Baba M: Induction of cellular resistance to nucleoside reverse transcriptase inhibitors by the wild-type breast cancer resistance protein. Biochem Pharmacol. 68:1363–1370. 2004. View Article : Google Scholar : PubMed/NCBI
13	Rehermann B and Naoumov NV: Immunological techniques in viral hepatitis. J Hepatol. 46:508–520. 2007. View Article : Google Scholar : PubMed/NCBI
14	König J, Hartel M, Nies AT, Martignoni ME, Guo J, Büchler MW, Friess H and Keppler D: Expression and localization of human multidrug resistance protein (ABCC) family members in pancreatic carcinoma. Int J Cancer. 115:359–367. 2005.PubMed/NCBI
15	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCRand the 2(−Delta Delta C(T)) method. Methods. 25:402–408. 2001.
16	Doyle LA, Yang W, Abruzzo LV, Krogmann T, Gao Y, Rishi AK and Ross DD: A multidrug resistance transporter from human MCF-7 breast cancer cells. Proc Natl Acad Sci USA. 95:15665–15670. 1998. View Article : Google Scholar : PubMed/NCBI
17	Lee CG and Gottesman MM: HIV-1 protease inhibitors and the MDR1 multidrug transporter. J Clin Invest. 101:287–288. 1998. View Article : Google Scholar : PubMed/NCBI
18	Srinivas RV, Middlemas D, Flynn P and Fridland A: Human immunodeficiency virus protease inhibitors serve as substrates for multidrug transporter proteins MDR1 and MRP1 but retain antiviral efficacy in cell lines expressing these transporters. Antimicrob Agents Chemother. 42:3157–3162. 1998.
19	Schuetz JD, Connelly MC, Sun D, Paibir SG, Flynn PM, Srinivas V, Kumar A and Fridland A: MRP4: A previously unidentified factor in resistance to nucleoside-based antiviral drugs. Nat Med. 5:1048–1051. 1999. View Article : Google Scholar : PubMed/NCBI
20	Huisman MT, Smit JW and Schinkel AH: Significance of P-glycoprotein for the pharmacology and clinical use of HIV protease inhibitors. AIDS. 14:237–242. 2000. View Article : Google Scholar : PubMed/NCBI
21	Poller B, Wagenaar E, Tang SC and Schinkel AH: Double-transduced MDCKII cells to study human P-glycoprotein (ABCB1) and breast cancer resistance protein (ABCG2) interplay in drug transport across the blood-brain barrier. Mol Pharm. 8:571–582. 2011. View Article : Google Scholar
22	Reid G, Wielinga P, Zelcer N, De Haas M, Van Deemter L, Wijnholds J and Borst P: Characterization of the transport of nucleoside analog drugs by the human multidrug resistance proteins MRP4 and MRP5. Mol Pharmacol. 63:1094–1103. 2003. View Article : Google Scholar : PubMed/NCBI
23	Borst P, Balzarini J, Ono N, Reid G, de Vries H, Wielinga P, Wijnholds J and Zelcer N: The potential impact of drug transporters on nucleoside-analog-based antiviral chemotherapy. Antiviral Res. 62:1–7. 2004. View Article : Google Scholar : PubMed/NCBI
24	Janneh O, Owen A, Chandler B, Hartkoorn RC, Hart CA, Bray PG, Ward SA, Back DJ and Khoo SH: Modulation of the intracellular accumulation of saquinavir in peripheral blood mononuclear cells by inhibitors of MRP1, MRP2, P-gp and BCRP. AIDS. 19:2097–2102. 2005. View Article : Google Scholar : PubMed/NCBI
25	de Maat MM, Ekhart GC, Huitema AD, Koks CH, Mulder JW and Beijnen JH: Drug interactions between antiretroviral drugs and comedicated agents. Clin Pharmacokinet. 42:223–282. 2003.PubMed/NCBI
26	Huisman MT, Smit JW, Wiltshire HR, Hoetelmans RM, Beijnen JH and Schinkel AH: P-glycoprotein limits oral availability, brain, and fetal penetration of saquinavir even with high doses of ritonavir. Mol Pharmacol. 59:806–813
27	Perloff ES, Duan SX, Skolnik PR, Greenblatt DJ and von Moltke LL: Atazanavir: effects on P-glycoprotein transport and CYP3A metabolism in vitro. Drug Metab Dispos. 33:764–770. 2005. View Article : Google Scholar : PubMed/NCBI
28	Ding R, Tayrouz Y, Riedel KD, Burhenne J, Weiss J, Mikus G and Haefeli WE: Substantial pharmacokinetic interaction between digoxin and ritonavir in healthy volunteers. Clin Pharmacol Ther. 76:73–84. 2004. View Article : Google Scholar : PubMed/NCBI
29	Hayashi K, Pu H, Tian J, Andras IE, Lee YW, Hennig B and Toborek M: HIV-Tat protein induces P-glycoprotein expression in brain microvascular endothelial cells. J Neurochem. 93:1231–1241. 2005. View Article : Google Scholar : PubMed/NCBI
30	Hayashi K, Pu H, Andras IE, Eum SY, Yamauchi A, Hennig B and Toborek M: HIV-TAT protein upregulates expression of multidrug resistance protein 1 in the blood-brain barrier. J Cereb Blood Flow Metab. 26:1052–1065. 2006. View Article : Google Scholar : PubMed/NCBI
31	Jorajuria S, Dereuddre-Bosquet N, Naissant-Storck K, Dormont D and Clayette P: Differential expression levels of MRP1, MRP4, and MRP5 in response to human immunodeficiency virus infection in human macrophages. Antimicrob Agents Chemother. 48:1889–1891. 2004. View Article : Google Scholar : PubMed/NCBI
32	Turriziani O, Gianotti N, Falasca F, Boni A, Vestri AR, Zoccoli A, Lazzarin A and Antonelli G: Expression levels of MDR1, MRP1, MRP4, and MRP5 in peripheral blood mononuclear cells from HIV infected patients failing ART. J Med Virol. 80:766–771. 2008. View Article : Google Scholar : PubMed/NCBI
33	Lucia MB, Savarino A, Straface E, Golotta C, Rastrelli E, Matarrese P, Rotella S, Malorni W and Cauda R: Role of lymphocyte multidrug resistance protein 1 in HIV infection: expression, function, and consequences of inhibition. J Acquir Immune Defic Syndr. 40:257–266. 2005. View Article : Google Scholar : PubMed/NCBI
34	Meaden ER, Hoggard PG, Maher B, Khoo SH and Back DJ: Expression of P-glycoprotein and multidrug resistance-associated protein in healthy volunteers and HIV-infected patients. AIDS Res Hum Retroviruses. 17:1329–1332. 2001. View Article : Google Scholar : PubMed/NCBI
35	Speck RR, Yu XF, Hildreth J and Flexner C: Differential effects of p-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis. 186:332–340. 2002. View Article : Google Scholar
36	Gupta S and Gollapudi S: P-glycoprotein (MDR 1 gene product) in cells of the immune system: its possible physiologic role and alteration in aging and human immunodeficiency virus-1 (HIV-1) infection. J Clin Immunol. 13:289–301. 1993. View Article : Google Scholar : PubMed/NCBI
37	Laupèze B, Amiot L, Payen L, Drénou B, Grosset JM, Lehne G, Fauchet R and Fardel O: Multidrug resistance protein (MRP) activity in normal mature leukocytes and CD34-positive hematopoietic cells from peripheral blood. Life Sci. 68:1323–1331. 2001.PubMed/NCBI
38	Albermann N, Schmitz-Winnenthal FH, Z’graggen K, Volk C, Hoffmann MM, Haefeli WE and Weiss J: Expression of the drug transporters MDR1/ABCB1, MRP1/ABCC1, MRP2/ABCC2, BCRP/ABCG2, and PXR in peripheral blood mononuclear cells and their relationship with the expression in intestine and liver. Biochem Pharmacol. 70:949–958. 2005. View Article : Google Scholar : PubMed/NCBI
39	Oselin K, Mrozikiewicz PM, Pähkla R and Roots I: Quantitative determination of the human MRP1 and MRP2 mRNA expression in FACS-sorted peripheral blood CD4+, CD8+, CD19+, and CD56+ cells. Eur J Haematol. 71:119–123. 2003. View Article : Google Scholar
40	Turriziani O, Di Marco P, Antonelli G and Dianzani F: May the drug transporter P glycoprotein affect the antiviral activity of human immunodeficiency virus type 1 proteinase inhibitors? Antimicrob Agents Chemother. 44:473–474. 2000. View Article : Google Scholar : PubMed/NCBI